Cyclerion Therapeutics
CYCN
73 hedge funds and large institutions have $140M invested in Cyclerion Therapeutics in 2020 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 19 increasing their positions, 25 reducing their positions, and 11 closing their positions.
33% more capital invested
Capital invested by funds: $105M → $140M (+$35M)
0.2% more ownership
Funds ownership: 3.19% → 3.38% (+0.2%)
9% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 11
1% less funds holding
Funds holding: 74 → 73 (-1)
24% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 25
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SPC
Slate Path Capital
New York
|
+$28.6M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.42M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$553K |
| 4 |
Charles Schwab
San Francisco,
California
|
+$341K |
| 5 |
Morgan Stanley
New York
|
+$310K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EP
Eversept Partners
New York
|
-$1.46M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$650K |
| 3 |
Renaissance Technologies
New York
|
-$502K |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$466K |
| 5 |
State Street
Boston,
Massachusetts
|
-$349K |
CYCN Hedge Fund Activity: Q3 2020 in Review
73 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Cyclerion Therapeutics (CYCN) for Q3 2020, worth a combined $140M — up 33% from $105M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of CYCN and 10 opened new positions — a net loss of 1 holder — while 25 trimmed existing stakes and 19 added.
The largest buyer was Slate Path Capital, adding an estimated $28.6M. The largest seller was Eversept Partners, exiting entirely with an estimated $1.46M sold.
- 73 institutional investors held Cyclerion Therapeutics (CYCN) as of Q3 2020, down from 74 in Q2 2020.
- Funds reported $140M of Cyclerion Therapeutics stock for Q3 2020, up 33% quarter-over-quarter.
- 10 funds opened new Cyclerion Therapeutics positions in Q3 2020 and 11 closed out, a net change of -1 holder.
- The largest Cyclerion Therapeutics buyer in Q3 2020 was Slate Path Capital, an estimated $28.6M added.
- The largest Cyclerion Therapeutics seller in Q3 2020 was Eversept Partners, an estimated $1.46M sold.
Based on aggregated 13F filings for Q3 2020.